Already a member?
Login
Become a member
Register
Home
About
About PCSK9 Forum
Editorial Board
Mission Statement
About PCSK9
What are PCSK9 inhibitors?
Why are new treatments needed?
Which patients may benefit?
News
News
Meeting Reports
Expert Meetings
Commentary
Hot topics
From the Editors
Questions of the Month
Slides
Trials
Videos
Resources
Trials
Events
Videos
Webcasts
Guidelines & Consensus Guidance
Article Archive
Contact
⇒ Main Menu
Home
About
– About PCSK9 Forum
– Editorial Board
– Mission Statement
– What are PCSK9 inhibitors?
– Why are new treatments needed?
– Which patients may benefit?
News
– News
– Meeting Reports
– Expert Meetings
– Hot topics
– From the Editors
– Questions of the Month
Slides
Trials
Videos
Resources
– Trials
– Events
– Videos
– Webcasts
– Guidelines & Consensus Guidance
– Article Archive
Contact
News
PCSK9 inhibition in heart failure
ASO-mediated reduction in Lp(a) levels: Update on Pelacarsen
A new ASO PCSK9 inhibitor: The Etesian study
siRNA-mediated lowering of Lp(a) by SLN360
CLEAR OUTCOMES: Topline data show bempedoic acid reduces cardiovascular events
Latest News Updates
News from the 10th Expert Meeting of the Editorial Board of PCSK9 Education and Research Forum
Posted on
31 July 2019
|
Related content